Wellington Management Group LLP Acquires Shares of 158,674 Anavex Life Sciences Corp. (NASDAQ:AVXL)

Wellington Management Group LLP acquired a new stake in Anavex Life Sciences Corp. (NASDAQ:AVXL - Free Report) during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm acquired 158,674 shares of the biotechnology company's stock, valued at approximately $1,704,000. Wellington Management Group LLP owned about 0.19% of Anavex Life Sciences as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in AVXL. Pier Capital LLC bought a new stake in Anavex Life Sciences during the fourth quarter worth about $4,746,000. Essential Planning LLC. acquired a new position in shares of Anavex Life Sciences during the 4th quarter worth approximately $4,437,000. Heartland Advisors Inc. acquired a new position in shares of Anavex Life Sciences during the 4th quarter worth approximately $1,674,000. Virtu Financial LLC bought a new stake in shares of Anavex Life Sciences during the 4th quarter worth approximately $967,000. Finally, Barclays PLC boosted its holdings in shares of Anavex Life Sciences by 70.4% in the 3rd quarter. Barclays PLC now owns 155,179 shares of the biotechnology company's stock valued at $882,000 after buying an additional 64,101 shares during the last quarter. Institutional investors own 31.55% of the company's stock.

Anavex Life Sciences Stock Up 1.2 %

Shares of AVXL stock traded up $0.11 during trading on Friday, reaching $8.95. 351,322 shares of the company's stock were exchanged, compared to its average volume of 1,252,047. Anavex Life Sciences Corp. has a twelve month low of $3.25 and a twelve month high of $14.44. The firm's fifty day moving average price is $8.72 and its 200-day moving average price is $8.62. The stock has a market capitalization of $761.32 million, a PE ratio of -16.27 and a beta of 0.80.

Anavex Life Sciences (NASDAQ:AVXL - Get Free Report) last released its quarterly earnings data on Wednesday, February 12th. The biotechnology company reported ($0.14) EPS for the quarter, beating the consensus estimate of ($0.17) by $0.03. As a group, analysts anticipate that Anavex Life Sciences Corp. will post -0.69 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on the stock. HC Wainwright reaffirmed a "buy" rating and set a $42.00 price target on shares of Anavex Life Sciences in a research report on Monday, April 7th. D. Boral Capital reaffirmed a "buy" rating and issued a $46.00 target price on shares of Anavex Life Sciences in a report on Monday, April 7th.

Anavex Life Sciences Company Profile

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.